HIF1A and pulmonary fibrosis: Administering pharmacological concentrations of AsA (an alternative to HIF-1 inhibitors) inhibited the progression of both cancer and underlying pulmonary fibrosis, with effects comparable to those seen with HIF-1α inhibitors.